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Brief Definit ive Report
DNA polymerases are required for DNA synthe-
sis. Mutations in DNA polymerases or changes 
in their expression could be manifested by altera-
tions in DNA replication, in cell cycle progres-
sion, and most prominently, in mutagenesis (Loeb 
and Monnat, 2008). Several different human 
diseases might present opportunities to identify 
disease-associated polymerase mutations and 
clarify their specific role and mechanisms. Muta-
tions that have a strong effect on function of 
the canonical DNA polymerases would prob-
ably lead to early embryonal or fetal lethality. 
In contrast, partial loss of function or haploin-
sufficiency might lead to either multisystem, 
organ-specific, or cell lineage–specific devel-
opmental defects or to the early exhaustion of 
continuously replicating cell lineages.
In this study, we describe a large, consanguin-
eous family in which mild facial dysmorphism, 
immunodeficiency, livedo, and short stature were 
associated in 11 affected subjects with genomic 
mutation in POLE1 (polymerase  1), resulting in 
haploinsufficiency. Of note, patients did not ex-
hibit cancer susceptibility. The findings indicate 
that Pol is primarily required for cell prolifera-
tion and early phase of cell cycle progression.
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DNA polymerase  (Pol) is a large, four-subunit polymerase that is conserved throughout 
the eukaryotes. Its primary function is to synthesize DNA at the leading strand during 
replication. It is also involved in a wide variety of fundamental cellular processes, including 
cell cycle progression and DNA repair/recombination. Here, we report that a homozygous 
single base pair substitution in POLE1 (polymerase  1), encoding the catalytic subunit  
of Pol, caused facial dysmorphism, immunodeficiency, livedo, and short stature (“FILS  
syndrome”) in a large, consanguineous family. The mutation resulted in alternative splicing 
in the conserved region of intron 34, which strongly decreased protein expression of Pol1 
and also to a lesser extent the Pol2 subunit. We observed impairment in proliferation and 
G1- to S-phase progression in patients’ T lymphocytes. Pol1 depletion also impaired  
G1- to S-phase progression in B lymphocytes, chondrocytes, and osteoblasts. Our results 
evidence the developmental impact of a Pol catalytic subunit deficiency in humans and  
its causal relationship with a newly recognized, inherited disorder.
© 2012 Pachlopnik Schmid et al. This article is distributed under the terms 
of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for 
the first six months after the publication date (see http://www.rupress.org/
terms). After six months it is available under a Creative Commons License 
(Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at 
http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Figure 1. Pedigree and clinical manifestations in patients with the FILS phenotype. (A) Pedigree of the family with FILS. Family members having 
provided DNA are numbered. Completely closed symbols indicate affected individuals, and half closed symbols indicate a heterozygous carrier. An arrow 
designates the index case. Individuals clustered in a diamond symbol in generation IV and V were not analyzed. Gray symbols indicate patients that did 
not undergo genetic testing. Slashes indicate deceased persons, double horizontal lines consanguinity, and dotted lines presumed interrelations. Case J* 
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RESULTS AND DISCUSSION
FILS syndrome manifestations
11 members of a large, consanguineous French kindred dis-
played mild facial dysmorphism, immunodeficiency, livedo, 
and short stature (referred to by us as “FILS syndrome”). Three 
additional members displayed two or three of these four fea-
tures. The pedigree and clinical features of the family members 
investigated in the present study are shown in Fig. 1, Table 1, 
and Table S1. One affected individual (VI-11) has four chil-
dren and so the syndrome is not associated with (male) infertil-
ity (Fig. 1 A). The patients had mild facial dysmorphism with 
malar hypoplasia (Fig. 1 B) and a high forehead. Livedo on the 
cheeks, forearms, and/or legs was present in all but one patient 
and noticed since birth in numbers of them (Fig. 1 B). There 
was no ulceration. With increasing age, telangiectasia was 
observed on the cheeks. Patients were born at term with a 
normal gestational weight and length. Growth impairment was 
observed during early childhood and resulted in shortness of 
height in adulthood, though to varying degree (Fig. 1 C). The 
mean height of the unaffected siblings was around the 50th 
percentile. Growth hormone production and response were 
tested in three patients and found to be normal. The head cir-
cumference was normal in all but one patient (VI-3), and thus 
the FILS patients had a relative macrocephaly. Patients VI-3, 
VI-11, and VI-29 had bone dysplasia and suffered from pain in 
the extremities; lacunar bone lesions, cortical thickening, and 
modeling defects at the long bone diaphyses were found in the 
three patients, whereas striae in the metaphyses were observed 
in patient VI-3 only (Fig. 1 D).
All but two of the patients with a FILS phenotype suf-
fered from an immunodeficiency that gave rise to medical 
evaluation in the index patient VI-12. Since their first year of 
life, patients had recurrent upper and lower respiratory tract 
infections, recurrent pulmonary infections resulting in two 
patients in bronchiectasis (patients VI-31 and VI-36), and recur-
rent meningitis caused by Streptococcus pneumonia. Patient J* 
died during a pulmonary infection at the age of 2 yr. Immuno-
logical experiments of the patients (Fig. 1, E and F; Table 1; 
and Table S1) showed decreased IgM and IgG2 levels, reduced 
isohemagglutinin titers, and a predominant lack of antibodies 
to polysaccharide antigens. Patients had low memory (CD27+) 
B cell counts, but the proportion of switched B cells (--) and 
nonswitched memory B cells were equally affected. The IgM, 
IgG, and IgA B cell repertoires in blood lymphocytes per-
formed in one patient (VII-1) showed a normal distribution of 
VH family usage (not depicted). B cell proliferation and switch 
to IgE production were normal upon stimulation with IL-4 and 
CD40 ligand in vitro (not depicted). In addition, several pa-
tients had low naive T cell counts and decreased T cell prolifer-
ation (Table S1). Immunoscope analysis of T cells in one 
patient (VII-1) showed a normally diversified TCR V reper-
toire (not depicted). Allergies, autoimmunity, opportunistic in-
fections, and malignancies were not observed in these patients. 
Although FILS patients’ phenotype resembled the one observed 
in Bloom’s disease, sister chromatid exchange was normal.
Identification of a mutation in POLE1
To identify the causal gene underlying the FILS syndrome 
and based on an assumption of autosomal recessive inheri-
tance, single nucleotide polymorphism (SNP) array genome-
wide homozygosity mapping was performed. This revealed 
a common 2-Mb region located at the end of chromosome 
12q containing 28 annotated genes, with a logarithm of the 
odds ratio (LOD score) of 11 (Fig. 2 A). Sequencing of the 
coding exons of candidate genes with functions related to cell 
division or cell growth, checkpoint with forkhead associated and 
ring finger (CHFR), DEAD box protein 51 (DDX51), Zinc 
finger 605 (ZNF605), ZNF140, nucleolar complex associated 
4 homologue (NOC4L), and POLE1 revealed in the 14 patients 
a homozygous nucleotide substitution at position 3 in intron 
34 (g.G4444+3 A>G) in the POLE1 gene (Fig. 2 A). Exome 
sequencing in one of the patients (VI-28) also identified this 
substitution and showed that POLE1 was the only mutated 
gene within the defined genetic linkage region on chromo-
some 12q. All tested parents were heterozygous for the muta-
tion. The mutation was absent from control populations, 
in-house exome sequencing data, and all publically available 
databases (including the dbSNP129 and 1000 Genomes data-
sets). Heterozygous individuals were asymptomatic.
The g.G4444+3 A>G mutation’s impact on mRNA splic-
ing was then evaluated. Using primers located in exons 32 and 
37 (which thus flanked intron 34), two PCR products were 
separated on agarose gels from homozygous and heterozygous 
individuals (six patients and three parents), whereas a single 
band was found in control individuals (Fig. 2 B). Sequencing 
of the smaller PCR product (predominant in the patients) 
identified a POLE1 species lacking exon 34 (Fig. 2, B and C). 
Sequencing of the larger PCR product identified WT POLE1 
sequence in control samples and the parents’ samples and a 
mixed sequence in the patients’ samples (Fig. 2, B and C). 
After amplifying and cloning the upper band from two patients 
(VI-39 and VII-1), we found (a) a WT sequence in 63% of 46 
clones and (b) deletion of exon 34 in 30% of them. Two other 
clones had different frame-shifted insertions and deletions. 
died after a pulmonary infection at the age of 2 yr. (B) Facial profile photographs showing patient VI-36 at the age of 9, with livedo on the cheek and 
discrete malar hypoplasia (left), telangiectasia on the cheek of patient VI-11 at the age of 33 (middle) and, lastly, livedo on the thigh of patient VI-11 
(right). (C) Growth charts for male (left) and female (right) patients, showing short stature in all instances and particularly substantial growth impairment 
in patients VI-3, VI-10, VI-11, VI-12, VI-28, and VII-1. (D) X ray of the forearm of case VI-3 (left) and patient VI-29 (middle) showing irregular diaphyseal 
hyperostosis (arrows) and x-ray of the leg of patient VI-29 (right) showing irregular diaphyseal hyperostosis and metaphyseal striations (arrow). (E) IgM levels 
in patients (closed dots) and heterozygous individuals (open dots) of different ages. The shaded area indicates our in-house normative values. (F) Percentages 
of memory B cells (CD27+/CD19+) in patients (closed dots). The shaded area indicates normal level from in-house control values.
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Li et al., 1997). Protein expression of Pol3 was normal 
(not depicted). Protein expression of Pol2 was also sub-
normal in heterozygous individuals but was not as low as 
in the patients (not depicted).
Impaired proliferation and cell cycle  
progression of Pol-deficient cells
In eukaryotes, DNA polymerases , , and  jointly enable 
DNA replication (Hubscher et al., 2002). DNA replication 
is initiated by the Pol–primase complex, which synthesizes 
short, primed templates. Next, Pol and Pol tether to primed 
templates and are thought to replicate the leading and lag-
ging strands, respectively (Loeb and Monnat, 2008). To assess 
the POLE1 mutation’s cellular consequences, we used a se-
quential CFSE dilution assay to analyze the T lymphocytes’ 
ability to proliferate in response to anti-CD3 and IL-2 stim-
ulation. In contrast, to control lymphocytes, a significant pro-
portion of the patients’ T lymphocytes had not divided at 
day 4 (Fig. 3 A). This was not a consequence of defective cell 
activation or elevated cell death because the proportion of 
CD25- and annexin-V–positive cells, respectively, were simi-
lar in cell samples from patients and controls (not depicted). 
We next looked at whether low Pol1 levels modified the cell 
cycle progression. A cell cycle distribution analysis was per-
formed using propidium iodide and 5-ethyl-2-deoxyuridine 
(EdU) labeling in primary T lymphoblasts from seven pa-
tients and in a lymphoblastoid B cell line (LBL) from patient 
VI-29. We observed a strikingly higher proportion of Gap 1 
(G1)–phase nuclei in CD4 and CD8 T lymphocytes from 
the patients and a corresponding lower proportion of syn-
thesis (S)-phase nuclei, when compared with WT controls 
(Fig. 3 B). Similar results were obtained with the patient 
VI-29 LBL, whereas LBL from a heterozygous subject (V-9) 
displayed an intermediate phenotype (Fig. 3 C). This phe-
notype was dramatically exacerbated when the residual level 
of Pol1 protein expressed in VI-29 LBL cells was reduced 
Thus, individuals with the g.G4444+3 A>G substitution have 
two major POLE1 transcripts: WT and exon 34 deleted 
(Fig. 2 C). The proportion of the WT POLE1 transcript in 
T lymphoblasts was significantly lower in patients (by around 
90%) than in control individuals, whereas the total overall 
amount of POLE1 transcripts did not differ significantly as 
determined by quantitative PCR. These data confirm that the 
major transcript in FILS patients was exon 34 del POLE1.
Impaired expression of POL1 and POL2
The 49 coding exons of POLE1 are translated into a 2,286-
residue protein. It comprises a large N-terminal catalytic do-
main with exonuclease and polymerase motifs and a C-terminal 
domain containing binding sites for the small subunits of the 
Pol holoenzyme. Deletion of POLE1 exon 34 would lead 
to a subsequent frame shift (from S1483V onwards) and a 
premature stop codon at position 1561 in the new protein, 
which would thus lack the C-terminal half (Fig. 2 D). How-
ever, we could not detect any truncated protein in lym-
phocyte samples (from five patients and three heterozygous 
individuals). In contrast, severely decreased expression of full-
length Pol1 was found in the patients and, to a lesser extent, 
in the heterozygous individuals (Fig. 2 E). In addition to 
Pol1, the Pol holoenzyme comprises three additional sub-
units: Pol2, Pol3, and Pol4. It has been assumed that 
Pol2 stabilizes the catalytic Pol1 (Li et al., 1997). Pol2, 
Pol3, and Pol4 also interact with other proteins and with 
DNA (Dua et al., 1999; Li et al., 2000; Shikata et al., 2006; 
Bermudez et al., 2011) and are thus likely to influence the 
holoenzyme’s functional state. We therefore investigated 
the expression of the other three Pol subunits. There were 
no significant differences between patients and controls in 
terms of the transcript levels of POLE2, POLE3, and POLE4 
(not depicted). In contrast, protein expression of Pol2 
was found to be abnormally low, supporting a role in turn 
of the catalytic subunit in stabilizing Pol2 (not depicted; 
Table 1. Clinical and laboratory summary of the FILS patients
Parameter Patient ID
V-1 VI-3 VI-9 VI-10 VI-11 VI-12 VI-28 VI-29 VI-31 VI-36 VI-38 VI-39 VII-1 VII-2
Gender m f m m m f f m m f f m m f
Age at last follow 
up (yr)
17 23 25 24 33 31 3 11 17 10 8 6 11 6
Recurrent respiratory 
infections
+ + + +  + + + + +  + + +
Facial dysmorphy + + + + + + +  + + + + + +
Livedo + + + + + + +  + + + + + +
Bone disease  +   +   +      
Short stature (+) +  + + ++ ++ (+) (+) + nd (+) ++ (+)
IgM ↓ ↓ nd ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓
Anti–S. pneumoniae 
polysaccharide IgG
↓ nd nd nd nd nd ↓ nd ↓ ↓ ↓ ↓ ↓ ↓
f, female; m, male; nd, not done. For Short stature, “+” indicates less than 2 SD; “(+)” indicates 2 SD; and “++” indicates 4 SD or less. For IgM, ”↓” indicates below 2 SD.  
For Anti–S. pneumoniae polysaccharide IgG, ”↓” indicates antibody titer increase after nonconjugate anti-pneumococcal 23-valent vaccine less than fourfold.
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Pol and Pol expression in various cell types
The fact that yeast Pol mutants are viable (Kesti et al., 1999) 
suggests that another polymerase can perform support repli-
cation of leading strand in some contexts. Pol is a likely 
candidate. We investigated the distribution of POLE1 and 
POLD transcript expression in various human cell types and 
found that the relative expression of POLE1 to POLD was 
higher in PBMCs, chondrocytes, osteoblasts, osteoclasts, B cells, 
and testis cells than in the other cell types analyzed (Fig. 3 H). 
This differential expression may contribute to the tissue-specific 
consequences of the low Pol1 levels found in affected indi-
viduals. Of note, POLE1 is much higher expressed in B lym-
phocytes than in T lymphocytes, which may account for the 
more sever B cell than T cell defect that characterized the 
patients’ phenotype. Pol expression by VI-29 LBL was com-
parable with control (not depicted).
further by POLE1 shRNA (Fig. 3, D and E). Thus, the ob-
served phenotype correlated with the extent of POLE1 tran-
script depletion. Given the short stature displayed by the 
patients affected by FILS syndrome and the bone anomalies 
observed in some of the individuals, we also looked at whether 
POLE1 depletion also affected cell cycle progression in chon-
drocyte and osteoblast cell lines. Indeed, a similar impairment 
in the G1- to S-phase transition was observed in both cell 
lines after Pol1 depletion with a specific shRNA (Fig. 3 F 
and not depicted). To determine whether POLE1 was suffi-
cient to explain the patients’ functional defects, we reconsti-
tuted POLE1 expression by lentiviral transduction of patient 
LBLs. WT POLE1 expression in the patient LBLs restored 
S-phase progression to a level similar to the one observed in 
control LBLs (Fig. 3 G). Expression of an empty vector had 
no effect (not depicted).
Figure 2. Homozygous single base pair substitution in POLE1. (A) Schematic representation of the candidate interval on the long arm of chromo-
some 12 defined by linkage analysis and the intronic nucleotide substitution (g.G4444+3 A>G) between exons 34 and 35. (B) At the cDNA level, the muta-
tion results in two distinct POLE1 transcripts, a WT transcript (POLE1 WT) and a transcript deleted of exon 34 (POLE1 34), accounting for 10% and 90% 
of the POLE1 transcript expressed in patients cells, respectively. (C) Electropherograms of POLE1 cDNA obtained by sequencing the upper and lower bands, 
highlighting the exon 34 deletion in the lower band (bottom left). (D) Schematic representation of the predicted effect of the aberrant splice on the Pole1 
protein. The intronic mutation results in an alternative splice, which deletes 51 aa in the WT protein leading to frameshift and premature stop codon at 
position 1561. (E) Pol1 protein levels in LBLs from a FILS patient (VI-29) and a heterozygous individual (V-9) compared with a control subject. Actin was 
used as a loading control. This Western blot is representative of three experiments.
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Figure 3. Impaired proliferation and cell cycle kinetics in Pol1-deficient cells. (A) Proportions of proliferating CD4+ and CD8+ T cells at day 4 
after CFSE labeling and OKT3/IL-2 stimulation. Each point represents one patient (*, P < 0.05; **, P < 0.005). (B) Quantification of EdU incorporation by 
CD4+ and CD8+ T cells obtained from controls and FILS patients. Each point represents one patient (**, P < 0.005). The cell cycle was measured by EdU 
incorporation and propidium iodide labeling of cells cultured for 5 d after stimulation with aCD3/CD28 beads. Cells were labeled with EdU for 1 h before 
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This study is the first to report an association between 
a mutation in the POLE1 gene and a human disorder. 
Mice with disruption of Pole1 gene die in utero (Mouse 
Genome Informatics, http://www.informatics.jax.org/marker/
MGI:1196391), whereas those with knockin allele resulting in 
loss of Pol proofreading, while retaining polymerase activity, 
die prematurely of intestinal adenomas and adenocarcinomas 
(Albertson et al., 2009). The splice mutation observed here was 
associated with residual expression of 10% of normal protein 
levels. Affected family members do not exhibit cancer suscep-
tibility. Nonetheless, FILS patients had congenital abnormalities, 
including mild facial dysmorphic features, immunodeficiency, 
livedo, and short stature. Decreased expression of Pol1 pri-
marily results in alteration of the cell cycle kinetics, with a pro-
longed G1 phase, delayed S-phase entry, and thus restricted 
cell proliferation. This phenotype was observed in all cell types 
tested, including the T and B lymphocytes, chondrocytes, and 
osteoblasts that strongly express Pol1 and are relevant to the 
manifestations in FILS syndrome. We found that Pol1 pro-
motes S-phase entry in these cells, rather than S-phase pro-
gression as previously reported in fibroblasts (Bermudez et al., 
2011). Although residual Pol1 protein expression and the po-
tential redundancy with Pol function may explain the par-
tially preserved cell growth, a partial Pol1 deficiency appears 
to have important developmental consequences. Further stud-
ies are needed to provide details of the mechanisms by which 
lymphocytes, mostly B lymphocytes, cartilage, and bone cells 
(chondrocytes and osteoblasts) and possibly endothelial cells 
are affected by low Pol1 protein levels. These findings suggest 
that patients with a FILS phenotype could be usefully screened 
for mutations in the genes encoding Pol1 and the other sub-
units of the Pol complex.
MATERIALS AND METHODS
SNP linkage analysis and sequence analysis. Genomic DNA was iso-
lated by phenol/chloroform extraction. A genome-wide linkage study was 
performed using Affymetrix GeneChip Mapping 250 K NspI as described 
elsewhere (Côte et al., 2009). Homozygous regions were detected using a 
parametric, SNP-based linkage analysis (MERLIN software, version 1.1.1). 
Genomic DNA and cDNA were amplified, sequenced, and analyzed on an 
ABI Prism 3700 system (using a BigDye Terminator sequencing kit; Applied 
Biosystems). The impact of the intronic mutation on splicing was analyzed 
using primers located on exons 32 and 37 to amplify cDNA (Table S2). 
Exome sequencing analysis of a DNA sample from a FILS patient was per-
formed as described elsewhere (Le Goff et al., 2012).
Growth charts. Curves were adapted from the World Health Organization 
growth charts (Braegger et al., 2011).
Cell cultures. Lymphoblasts were obtained by incubating PBMCs for 72 h 
with PHA (1:400 dilution; Sigma-Aldrich) and 20 IU/ml IL-2 (PeproTech) 
in Panserin medium (Biotech GmbH) supplemented with 10% human 
AB serum (Etablissement Français du Sang). Proliferation and IgE class 
switch recombination in blood lymphocytes were assessed after activation 
with 500 ng/ml sCD40 Ligand (Amgen) and 100 U/ml IL-4 (R&D Systems) 
as described elsewhere (Imai et al., 2003). Primary human chondrocytes and 
osteoblasts were immortalized by transfection with Simian virus 40 large 
T-antigen (SV40-TAg) as previously reported (Benoist-Lasselin et al., 2007). 
Osteoclasts were obtained from human PBMCs in the presence of M-CSF 
and RANKL (Chabbi-Achengli et al., 2012). Osteoclast mRNA was 
provided by M.C. de Vernejoul (INSERM U606 and Université Paris 
Descartes–Sorbonne Paris Cité, Paris, France).
Detection of apoptotic cells with annexin-V. The proportion of viable 
cells was determined by using the Annexin-V PE Apoptosis Detection kit I 
(BD). Cell fluorescence was measured on a FACSCanto (BD).
Gene expression analysis. Total RNA was isolated from the different cell 
types using the RNeasy Mini kit (QIAGEN), depleted in genomic DNA, 
and then reverse-transcribed into cDNA using QuantiTect (QIAGEN). 
Quantitative PCR was performed on cDNA using SYBR Green PCR Master 
mix (Applied Biosystems) and POLE1- and actin-specific primers (Table S2). 
Fluorescence during PCR and subsequent dissociation was measured in trip-
licates on an ABI 7900 cycler and analyzed using Sequence Detection Sys-
tems software (version 2.2.2; Applied Biosystems).
Protein blotting. Lymphoblasts were lysed in radioimmunoprecipitation 
(RIPA)/glycerol buffer (50 mM Hepes, 150 mM NaCl, 10% glycerol, 1% 
Triton X-100, 2 mM EDTA, and 1% sodium deoxycholate) supplemented 
with protease (Roche) and phosphatase (Sigma-Aldrich) inhibitors. Cell ex-
tracts were separated by SDS-PAGE, blotted, and then stained with anti-
Pol antibody 3C5.1 (Santa Cruz Biotechnology, Inc.), anti-Pol2 antibody 
clone 1A3 (Abcam), and anti-Pol3 antibody (Bethyl Laboratories, Inc). 
Anti-Pol4 antibody (Abnova) did not detect any proteins at the expected 
position (12 kD) in lymphocyte cell lysates from healthy individuals. Thus, 
the results are not shown. After staining with an HRP-conjugated secondary 
antibody, the immunoblot was developed with an Enhanced Chemilumi-
nescence Detection kit (GE Healthcare). The intensity of the immunoblot 
bands was quantified using Photoshop software (Adobe).
Flow cytometry. Antibodies were purchased from eBioscience or BD; 
standard flow cytometry methods were used for staining cell surface markers. 
For B cell analysis, blood lymphocytes were stained with allophycocya-
nin anti-CD19 (BD), FITC–anti-CD27 (BD), biotin anti-IgM (Jackson 
ImmunoResearch Laboratories, Inc.), streptavidin-PerCP antibody (BD), and 
R-PE–anti-IgD (Harlan Sera-Lab). Data were collected on a FACSCanto 
system and analyzed with FlowJo 8.8.4 software (Tree Star).
fluorescence-activated cell sorting analysis. Cells in the G1 phase enter early S phase (2N) and progress to late S phase (4N) and G2 phase. Gates defined 
the percentage of cells in G1, S (EdU positive), and G2 phases, as presented in the inset. (A and B) Horizontal lines indicate the mean. (C) Cell cycle distri-
bution of LBLs from patient VI-29, his parent (V-9), and a control. Data are representative of five independent experiments. (D) Pol1 protein levels in LBLs 
transfected with specific shRNA targeting POL1 or control shRNA. Actin was used as loading control. The black line indicates that intervening lanes have 
been spliced out. (E) Effect of depleting POL1 by specific shRNA (PolE-plVxKO-GFP vector) on the accumulation of cells in G1 phase in LBLs from a FILS 
patient and a control. The cell cycle in LBLs was measured by EdU incorporation after 72 h of transduction with specific shRNA (PolE-plVxKO-GFP vector). 
(F) Effect of depleting POL1 by specific shRNA (PolE-plVxKO-GFP vector) on the cell cycle progression (as measured by EdU incorporation) in SV40-
TAg–chondrocytes and SV40-TAg–osteoblasts. (G) Complementation of cell cycle progression by lentiviral transduction of LBLs from a FILS patient (VI-29) 
with WT POLE1 (PolE-pLenti7.3-GFP vector) as compared with nontransduced cells in the same experiment. Data are representative of three independent 
experiments. (H) Relative amounts of POLE and POLD transcript levels in different tissues, as measured by quantitative RT-PCR and normalized against the 
housekeeping gene GAPDH. Values represent mean ± SD calculated from two independent experiments.
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